Cargando…
Three-year follow-up of high-risk keratoplasty following fine-needle diathermy of corneal neovascularization combined with bevacizumab
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203370/ https://www.ncbi.nlm.nih.gov/pubmed/34989865 http://dx.doi.org/10.1007/s00417-021-05546-w |
| _version_ | 1784728699981004800 |
|---|---|
| author | Mestanoglu, Mert Händel, Alexander Cursiefen, Claus Hos, Deniz |
| author_facet | Mestanoglu, Mert Händel, Alexander Cursiefen, Claus Hos, Deniz |
| author_sort | Mestanoglu, Mert |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9203370 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92033702022-06-18 Three-year follow-up of high-risk keratoplasty following fine-needle diathermy of corneal neovascularization combined with bevacizumab Mestanoglu, Mert Händel, Alexander Cursiefen, Claus Hos, Deniz Graefes Arch Clin Exp Ophthalmol Letter to the Editor Springer Berlin Heidelberg 2022-01-06 2022 /pmc/articles/PMC9203370/ /pubmed/34989865 http://dx.doi.org/10.1007/s00417-021-05546-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter to the Editor Mestanoglu, Mert Händel, Alexander Cursiefen, Claus Hos, Deniz Three-year follow-up of high-risk keratoplasty following fine-needle diathermy of corneal neovascularization combined with bevacizumab |
| title | Three-year follow-up of high-risk keratoplasty following fine-needle diathermy of corneal neovascularization combined with bevacizumab |
| title_full | Three-year follow-up of high-risk keratoplasty following fine-needle diathermy of corneal neovascularization combined with bevacizumab |
| title_fullStr | Three-year follow-up of high-risk keratoplasty following fine-needle diathermy of corneal neovascularization combined with bevacizumab |
| title_full_unstemmed | Three-year follow-up of high-risk keratoplasty following fine-needle diathermy of corneal neovascularization combined with bevacizumab |
| title_short | Three-year follow-up of high-risk keratoplasty following fine-needle diathermy of corneal neovascularization combined with bevacizumab |
| title_sort | three-year follow-up of high-risk keratoplasty following fine-needle diathermy of corneal neovascularization combined with bevacizumab |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203370/ https://www.ncbi.nlm.nih.gov/pubmed/34989865 http://dx.doi.org/10.1007/s00417-021-05546-w |
| work_keys_str_mv | AT mestanoglumert threeyearfollowupofhighriskkeratoplastyfollowingfineneedlediathermyofcornealneovascularizationcombinedwithbevacizumab AT handelalexander threeyearfollowupofhighriskkeratoplastyfollowingfineneedlediathermyofcornealneovascularizationcombinedwithbevacizumab AT cursiefenclaus threeyearfollowupofhighriskkeratoplastyfollowingfineneedlediathermyofcornealneovascularizationcombinedwithbevacizumab AT hosdeniz threeyearfollowupofhighriskkeratoplastyfollowingfineneedlediathermyofcornealneovascularizationcombinedwithbevacizumab |